Your Client Rank:
Loading...
99
Updated 13-Dec-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 51.2% | 0.0% | -22.9% | -30.9% | | | | |
| Lilly | 18.9% | 0.4% | -4.4% | -10.5% | 9.5% | 0.0% | 30.7% | 31.2% |
| Vertex | 9.8% | 0.3% | 1.3% | -18.8% | 50.0% | -25.9% | >100% | >100% |
| Daiichi | 8.9% | 1.4% | 2.3% | -4.3% | 5.0% | 4.4% | 12.1% | 12.6% |
| AbbVie | 7.2% | 0.1% | -3.5% | -6.0% | 4.3% | -1.0% | 12.8% | 12.9% |
| Astra | 6.7% | 0.2% | -3.5% | -1.0% | 3.6% | 0.8% | 11.5% | 11.4% |
| Eisai | 6.3% | -1.0% | -0.4% | -5.3% | 14.5% | 1.7% | 18.8% | 18.9% |
| Novo | 6.1% | -0.5% | -0.4% | -0.9% | 0.1% | 0.9% | 5.9% | 6.1% |
| Sanofi | 5.7% | 1.0% | -2.2% | -1.5% | 4.4% | 0.4% | 8.0% | 9.2% |
| Chugai | 5.6% | 1.1% | -2.4% | -1.2% | 2.1% | -1.5% | 8.5% | 8.5% |
| Novartis | 5.5% | 0.1% | -1.6% | -0.1% | 1.0% | 0.2% | 6.6% | 8.2% |
| JNJ | 5.5% | -0.3% | -1.7% | -4.7% | 3.4% | 2.1% | 7.5% | 8.2% |
| Regeneron | 5.4% | 0.2% | -2.1% | 1.1% | 0.6% | 8.4% | 4.8% | 6.2% |
| Shionogi | 5.1% | -1.2% | 0.3% | -2.1% | -1.4% | 5.8% | 1.3% | 1.8% |
| Amgen | 4.0% | -0.1% | -1.8% | 2.9% | -0.6% | 2.0% | 4.7% | 4.8% |
| Gilead | 3.2% | -0.1% | -2.3% | -11.5% | 10.3% | -6.3% | 17.1% | 17.4% |
| Glaxo | 3.1% | 0.0% | -0.9% | 0.2% | 0.8% | 0.9% | 5.2% | 5.3% |
| Roche | 3.0% | -0.1% | -1.0% | -1.3% | 1.8% | 2.7% | 5.5% | 5.3% |
| Merck | 2.5% | 0.0% | -0.6% | -3.3% | 2.1% | -0.5% | 5.3% | 6.2% |
| Teva | 2.3% | 1.8% | -0.7% | -0.4% | 4.2% | 1.2% | 9.5% | 9.0% |
| Takeda | 1.5% | 0.3% | -0.7% | 0.4% | 16.5% | -8.0% | 6.7% | 4.7% |
| Lundbeck | 1.3% | 0.1% | -1.5% | 3.2% | 5.4% | 7.9% | 1.8% | -1.7% |
| Bayer | 1.0% | 1.2% | -1.7% | -1.0% | 16.3% | | 2.3% | 1.9% |
| Biogen | -0.8% | 0.3% | 0.7% | 0.3% | 0.5% | 2.7% | 0.3% | 0.0% |
| Pfizer | -4.2% | 0.2% | 0.4% | 2.6% | -1.8% | 1.4% | -6.0% | -6.2% |
| Astellas | -4.3% | -1.0% | -4.4% | 2.1% | 1.6% | -4.5% | -1.4% | -1.4% |
| Bristol | -4.9% | 0.2% | 1.0% | -13.3% | 27.1% | -20.4% | 35.4% | 35.6% |
| Neurocrine | | | | | | | | |
| EU Major | 4.4% | 0.4% | -1.8% | -0.7% | 3.0% | 0.5% | 6.8% | 6.9% |
| Other EU | 12.7% | 0.7% | -7.9% | -7.2% | 48.3% | -25.3% | >100% | |
| US Major | 4.8% | 0.3% | -1.9% | -6.8% | 6.0% | -1.5% | 11.5% | 17.7% |
| US Big Biotech | 4.3% | 0.1% | -1.9% | -6.1% | 5.5% | -2.4% | 11.9% | 10.3% |
| Other US | 2.3% | 1.8% | -0.7% | -0.4% | 4.2% | 1.2% | 9.5% | 9.0% |
| Japanese | 3.1% | 0.3% | -0.6% | -1.1% | 6.5% | -0.7% | 6.9% | 7.4% |
